These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9643535)

  • 1. Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity.
    Sharma S; Kochupillai V; Pati HP
    Med Oncol; 1998 Apr; 15(1):70-1. PubMed ID: 9643535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Karyotype conversion in two patients with chronic myeloid leukaemia after busulphan-induced marrow hypoplasia.
    Xue Y; Zhou XJ; Yu F; Gu J; Guo Y; Xie X; Lin B
    Br J Haematol; 1996 Mar; 92(4):944-6. PubMed ID: 8616090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
    Bowcock SJ; Galton DA; Goldman JM
    Eur J Haematol; 1989 May; 42(5):496-7. PubMed ID: 2567249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia.
    Radojkovic M; Ristic S; Colovic M; Todoric B; Krtolica K
    Med Oncol; 2001; 18(3):227-9. PubMed ID: 11917947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone.
    Mandigers CM; Mensink EJ; Geurts van Kessel A; van der Plas DC; Haanen C; Hagemeÿer A; de Witte T
    Ann Hematol; 1996 Jun; 72(6):371-3. PubMed ID: 8767106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cancer after busulphan treatment for chronic myeloid leukemia. A case report.
    Iurlo A; Foa P; Sala M; Maiolo AT
    Tumori; 1993 Aug; 79(4):278-9. PubMed ID: 8249184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy in a patient receiving busulphan for chronic myeloid leukaemia.
    Norhaya MR; Cheong SK; Hamidah NH; Ainoon O
    Singapore Med J; 1994 Feb; 35(1):102-3. PubMed ID: 8009265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.
    HAYHOE FG; KOK D
    Br Med J; 1957 Dec; 2(5059):1468-71. PubMed ID: 13489262
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent alopecia following chemotherapy and bone marrow transplantation.
    Tran D; Sinclair RD; Schwarer AP; Chow CW
    Australas J Dermatol; 2000 May; 41(2):106-8. PubMed ID: 10812705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cancer after busulphan treatment for chronic myeloid leukemia: therapeutic implications.
    Foa P; Iurlo A; Maiolo A
    Ann Oncol; 1993 Jun; 4(6):521-2. PubMed ID: 8353098
    [No Abstract]   [Full Text] [Related]  

  • 12. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia.
    Izumi T; Imagawa S; Hatake K; Miura Y; Ariyama T; Inazawa J; Abe T
    Int J Hematol; 1996 Jul; 64(1):73-7. PubMed ID: 8757971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies.
    Cony-Makhoul P; Marit G; Boiron JM; Puntous M; Reiffers J
    Bone Marrow Transplant; 1995 Jul; 16(1):69-70. PubMed ID: 7581131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
    Shepherd PC; Richards S; Allan NC
    Br J Haematol; 1994 Jan; 86(1):92-6. PubMed ID: 8011552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cataract after prolonged busulphan therapy.
    Soysal T; Bavunoğlu I; Başlar Z; Aktuğlu G
    Acta Haematol; 1993; 90(4):213. PubMed ID: 8140865
    [No Abstract]   [Full Text] [Related]  

  • 16. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
    Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
    Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
    Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
    [No Abstract]   [Full Text] [Related]  

  • 18. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.
    Shepherd PC; Fooks J; Gray R; Allan NC
    Br J Haematol; 1991 Oct; 79(2):185-92. PubMed ID: 1958475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia.
    Kitagawa S; Saito M; Miura Y
    Eur J Haematol; 1995 Oct; 55(4):285-6. PubMed ID: 7589353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.